ArticleOcular immunology and inflammation2025
Herpetic Eye Disease During the COVID-19 Pandemic at an Urban Hospital System.
Article in Ocular immunology and inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTo report and compare the incidence, prevalence, and presentation of herpetic eye disease (HED) before and during the COVID-19 pandemic in an urban hospital system and assess related COVID-19 infection or vaccination prior to presentation.
methodsA retrospective chart review of patients with herpes simplex virus (HSV) keratitis and HSV uveitis based on ICD-10 diagnosis codes at the University of Illinois Hospitals from before the COVID-19 pandemic (May 1, 2018, to February 29, 2020) and during the COVID-19 pandemic (March 1, 2020, to December 31, 2021) was performed. For each patient, demographic and clinical information was recorded. For patients seen during the pandemic, any history of COVID-19 infection or vaccination prior to HED presentation was recorded. For patients who presented with a history of COVID-19 infection or vaccination, further chart review was performed.
resultsSeventy-one patients (0.024%) out of 299,201 patients seen at the University of Illinois Hospitals presented with active HED in the period before the pandemic. Sixty-four patients (0.008%) out of 841,173 patients seen at the University of Illinois Hospitals presented with active HED in the period during the pandemic. Seventeen (26.6%) patients who presented during the pandemic had a history of COVID-19 infection or vaccination within 60 days prior to presentation.
conclusionUnderstanding the potential relationship between new presentations and recurrences of HED following COVID-19 exposure is important to consider with future COVID-19 infections and booster vaccinations. Providers should be aware of possible development of HED after COVID-19 vaccination or infection and should counsel patients accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.